GlassScriptPhysician profile
Kimberly M Smith
NPI 1053402339
$25,848.97
in general payments reported to CMS, 2019-2025
39 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,708 · 2022: $3,467 · 2023: $3,496 · 2024: $3,505 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,434 · Travel and Lodging: $538 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,496.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,433.86 |
| Travel and Lodging | $537.98 |
| Education | $206.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,839.41 | 2021-2025 | |
| Janssen Biotech, INC. | $7,036.38 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,390.80 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,044.41 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $547.49 | 2021-2025 | |
| Pfizer INC. | $481.40 | 2021-2025 | |
| Qol Medical, LLC | $420.37 | 2021-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $390.55 | 2021-2023 | |
| Ardelyx, INC. | $380.29 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $364.74 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $314.03 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $305.38 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $298.35 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $293.11 | 2021-2024 | Dificid |
| Intra-Sana Laboratories | $214.30 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205.74 | 2023-2025 | Omvoh |
| Genzyme Corporation | $185.51 | 2022-2025 | |
| Redhill Biopharma INC. | $147.93 | 2021-2024 | Talicia |
| Ferring Pharmaceuticals INC. | $136.14 | 2021-2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $114.61 | 2021-2024 | Givlaari |
| Daiichi Sankyo INC. | $103.46 | 2021-2023 | Injectafer |
| Braintree Laboratories, INC. | $72.63 | 2021-2024 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $60.96 | 2022-2024 | Tremfya |
| Enterra Medical, INC. | $60.12 | 2025 | |
| Baxter Healthcare | $56.37 | 2025 | Perclot |
| Pharmacyclics LLC, An Abbvie Company | $50.83 | 2023 | Imbruvica |
| Emd Serono, INC. | $44.61 | 2023 | Mavenclad |
| Novo Nordisk INC | $44.51 | 2025 | Wegovy |
| Celltrion USA INC. | $40.41 | 2025 | Vegzelma |
| Ancora Heart, INC. | $33.00 | 2023 | Accucinch |
| Ironwood Pharmaceuticals, INC | $26.49 | 2023-2024 | Linzess |
| Organon LLC | $22.94 | 2022 | |
| Boston Scientific Corporation | $21.19 | 2021 | |
| Intercept Pharmaceuticals, INC. | $20.93 | 2021 | |
| Fresenius Kabi USA, LLC | $17.69 | 2023 | Idacio |
| Medtronic, INC. | $17.64 | 2025 | Pillcam |
| Evoke Pharma, INC. | $17.55 | 2021 | |
| Vivus LLC | $15.02 | 2025 | Qsymia |
| Echosens North America, INC. | $11.68 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.